RedHill Biopharma (RDHL) Tops Q2 EPS by 52c, Beats on Revenues
Get Alerts RDHL Hot Sheet
Join SI Premium – FREE
RedHill Biopharma (NASDAQ: RDHL) reported Q2 EPS of ($0.06), $0.52 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $483 thousand versus the consensus estimate of $220 thousand.
For earnings history and earnings-related data on RedHill Biopharma (RDHL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gold Royalty Corp. (GROY) Tops Q4 EPS by 2c ; Offers Guidance
- MillerKnoll, Inc. (MLKN) Tops Q3 EPS by 1c; offers Q4 guidance
- Rex American Resources Corp. (REX) Tops Q4 EPS by 48c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!